A diagnostics startup co-founded by one of the pioneers of CRISPR gene editing has become the first to receive Food and Drug Administration authorization for a product that uses the technology – for a ...
Diagnostics developer Sherlock Biosciences has advanced its molecular diagnostic capabilities, which can now produce faster results on low-cost devices. The startup will use its Series B round of ...
Sherlock Biosciences has raised $35 million to use CRISPR and synthetic biology approaches for rapid disease detection. The company is based on CRISPR technology developed in the lab of Feng Zhang at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results